Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer

BACKGROUND: Among the solid tumors, human pancreatic ductal adenocarcinoma (PDAC) has the worst prognosis. Gemcitabine is the standard first line of therapy for pancreatic cancer but has limited efficacy due to inherent or rapid development of resistance and combining EGFR inhibitors with this regim...

Descripción completa

Detalles Bibliográficos
Autores principales: Venkatasubbarao, Kolaparthi, Peterson, Lindsay, Zhao, Shujie, Hill, Ping, Cao, Lin, Zhou, Qing, Nawrocki, Steffan T, Freeman, James W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3847497/
https://www.ncbi.nlm.nih.gov/pubmed/24025152
http://dx.doi.org/10.1186/1476-4598-12-104

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3847497/
https://www.ncbi.nlm.nih.gov/pubmed/24025152
http://dx.doi.org/10.1186/1476-4598-12-104

Ejemplares similares